FDA Approves Merck's Belzutifan for Advanced Renal Cell Carcinoma

Gelonghui December 15 | The U.S. Food and Drug Administration (FDA) approved Merck Sharp & Dohme AG's drug belzutifan for the treatment of advanced renal cell carcinoma (RCC) on Thursday.